依达拉奉联合神经节苷脂治疗急性脑梗死临床观察

Clinical observation of edaravone and ganglioside on treating acute ischemic stroke

目的应用临床病例对照试验评价依达拉奉联合神经节苷脂治疗急性缺血性脑卒中的临床疗效和安全性。方法选择符合入选标准的105例急性缺血性脑卒中患者,随机分为应用依达拉奉联合神经节苷脂组(联合用药组),单用神经节苷脂组,单用依达拉奉组,常规治疗组(对照组),各组常规治疗均采用抗血小板凝集、扩血管、活血化瘀等药物治疗,并酌情对症处理血压、血糖及电解质等。对比治疗前后神经功能缺损评分及格拉斯哥昏迷评分,判定疗效,计算有效率。结果联合用药组治疗脑梗死效果明显优于其他组,其神经功能缺损评分、格拉斯哥昏迷评分均优于其他组,差异有统计学意义(P<0.05)。结论依达拉奉联合神经节苷脂治疗急性缺血性脑卒中可更好地改善神经功能,降低致残率。

Objective To study the efficacy and safety of edaravone and ganglioside in the treatment of acute ischemic stroke by clinical case-control trial evaluation. Methods One hundred and five cases with acute isehemic stroke were randomly divided into three groups： edaravone combined ganglioside group （combined group）, single use of ganglioside group, single use of edaravone group. And conventional treatment group as control group, each routine treatment with antiplatelet aggregation, expanding blood vessel, promoting blood circulation and removing blood stasis, and control blood pressure, blood glucose and electrolytes. The score of neurological defect scores and Glasgow scores were ob- served before and after treatment to determine efficacy, calculation of efficiency. Results Treatment of the combined treatment group was significantly better than that of the other groups. The neurological defect scores and lasgow scores of cases in the treatment group were apparently better than those in the other group, the difference was statistically sig- nificant （P 〈 0.05）. Conclusion The treatment of acute ischemic stroke with edaravone and ganglioside can better im- prove neurological function and reduce disability.